期刊文献+

以自身免疫性溶血性贫血为首发表现的多发性骨髓瘤1例 被引量:3

下载PDF
导出
摘要 患者男,59岁。因乏力1个月余,于2012年3月2日入院。患者1个多月前无明显诱因感全身乏力,稍活动后即感双下肢酸软、气短难续,无其他不适。体检:T 38.5℃,BP 121/81 mmHg,R 20次/min,P 92次/min。贫血、消瘦貌,皮肤、巩膜轻度黄染,全身皮肤黏膜无淤点、淤斑,浅表淋巴结未及。胸骨无压痛,双肺呼吸音粗,右下肺可闻及少许湿性罗音。腹部、双肾检查无异常,双下肢无浮肿。神经系统检查无异常。
出处 《山东医药》 CAS 2014年第24期110-110,共1页 Shandong Medical Journal
  • 相关文献

参考文献6

  • 1孙莹,方美云,刘越坚.多发性骨髓瘤免疫表型特征及其意义[J].中国实验血液学杂志,2010,18(2):381-384. 被引量:20
  • 2Senapati SB,Mishra SS,Dhir MK,et al.A case of multiple myeloma presenting as scalp swelling with intracranial extension[J].J Neurosci Rural Pract,2013,4(4):445-448.
  • 3Livingood M,Newman SA.An unusual presentation of perforating metastatic calcino siscutis[J].Skinmed,2013,11(5):314-315.
  • 4戴秋新,徐昕,徐茂忠,赵钰,孟文俊.DVd方案治疗多发性骨髓瘤26例疗效观察[J].山东医药,2010,50(39):92-93. 被引量:3
  • 5Greenberg AJ,Rajkumar SV,Therneau TM,et al.Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma[J].Leukemia,2013(9):258.
  • 6Siegel D,Martin T,Nooka A,et al.Integrated safety profile of singleagent carfilzomib:experience from 526 patients enrolled in 4 phaseⅡclinical studies[J].Haematologica,2013,98(11):1753-1761.

二级参考文献20

  • 1庄俊玲,汪玄,武永吉.CD138/Syndecan-1在多发性骨髓瘤免疫表型中的意义[J].中国实验血液学杂志,2005,13(6):1023-1027. 被引量:10
  • 2Kara IO, Sahin B, Paydas S, et al. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Saudi Med J, 2004; 25( 11 ) : 1587 - 1592.
  • 3Braylan RC, Orfao A, Borowitz MJ, et al. Optimal number o4 reagents required to evaluate hematolymphoid neoplasia: results of an international consensus meeting. Cytometry, 2001 ;46 ( 1 ) :23 27.
  • 4Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol, 2004, 121 (4): 482-488.
  • 5Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purification of syndecan-1 ^+ malignant plasma cells. J lmmunol Methods, 1997 ;205 ( 1 ) :73 - 79.
  • 6Matsui W, Huff CA, Wang QJ, et al. Characterization of clonogenic multiple myeloma cells. Blood, 2004 ; 103 (6) : 2332 - 2336.
  • 7Aref S, Goda T, El-Sherbiny M. Syndecan-I in multiple myeloma: relationship to conventional prognostic factors. Hematology, 2003 ; 8(4) :221 -228.
  • 8Yang Y, Yaccoby S, Liu W. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002 ;100(2) :610 -617.
  • 9Bashey A, Cantwell MJ, Kipps TJ, et al. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol, 2002 ; 118 (2) :506 - 513.
  • 10Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res, 2005 ; 11 (10) : 3661 - 3667.

共引文献21

同被引文献19

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部